Terazosin, as a derivative of prazosin, is a long-acting selective α1 adrenal receptor blocker, which is widely used in the treatment of hypertension and benign prostatic hyperplasia due to its good water solubility, high bioavailability and long half-life. Recent studies have found that TZ can activate intracellular phosphoglycerate kinase1(Pgk1) in a specific dose range to protect the neurons and may be beneficial for the treatment and prevention of Parkinson’s disease (PD). This effect may be related to the improvement of cell energy metabolism, the increase of intracellular ATP concentration and the activation of Hsp90 caused by the activation of Pgk1. This indicates a new clinical application prospect of terazosin. This article will review and summarize the research progress of TZ in the newly discovered pharmacological mechanism and potential clinical application prospect, and discuss the possible research direction in the future.